Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRA023 (MK-7240, tulisokibart) in systemic sclerosis-associated interstitial lung disease
2023-509743-27-00Phase 2Completed
- Sponsor
- Prometheus Biosciences
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 19
01
Overview
Phase 2, randomised, double-blind trial in pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD) comparing tulisokibart with placebo (2 arms). Primary endpoints: Safety adverse events and Annual rate of change in FVC (mL) over 50 weeks. Started Jul 2024; status: completed.
02
Drugs
tulisokibart
03
Conditions
pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD)
Beyond the preview
Go deeper on 2023-509743-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509743-27-00.